Clinical Trials Logo

Laparoscopic Cholecystectomy clinical trials

View clinical trials related to Laparoscopic Cholecystectomy.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06321185 Recruiting - Clinical trials for Laparoscopic Cholecystectomy

Laparoscopic Cholecystectomy and Quality of Recovery

Start date: March 25, 2024
Phase: N/A
Study type: Interventional

This clinical trial aims to compare the Quality of Recovery-15 (QoR-15) scale scores in three groups of patients undergoing laparoscopic cholecystectomy. The first group will be applied subcostal transversus abdominis plane (subcostal TAP) block, the second group will receive local anesthetic infiltration into port sites, and the third group will receive only IV analgesics.

NCT ID: NCT06236074 Recruiting - Clinical trials for Laparoscopic Cholecystectomy

Comparison of Modified Post-Anesthetic Discharge Scoring System (PADSS) Between 4 and 24 Hours in Patients Undergoing Laparoscopic Cholecystectomy

Start date: January 24, 2024
Phase: N/A
Study type: Interventional

This study is compare of Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours in patients undergoing laparoscopic cholecystectomy

NCT ID: NCT06022926 Recruiting - Clinical trials for Laparoscopic Cholecystectomy

Investigation of the Intraoperative and Postoperative Effects of Warming Patients in Laparoscopic Cholecystectomy

Start date: October 3, 2023
Phase: N/A
Study type: Interventional

In our study, the investigators will investigate the effects of electric blanket heating on intraoperative hemodynamics, postoperative nausea, vomiting, shivering, agitation and pain in patients undergoing laparoscopic cholecystectomy under general anesthesia.

NCT ID: NCT06017167 Recruiting - Clinical trials for Postoperative Nausea and Vomiting

Prophylaxis Against Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

Start date: September 15, 2022
Phase: Phase 2
Study type: Interventional

The aim of the study is to compare antiemetic effects between dexmedetomidine and ondansteron in the first group versus dexamethasone and ondansteron in the second group. The primary outcome in this study is incidence of postoperative nausea and vomiting after laparoscopic cholecystectomy. The secondary outcomes are: - The severity of post operative nausea and vomiting. - Use of rescue antiemetic drugs. - Postoperative pain and sedation.

NCT ID: NCT05988671 Recruiting - Clinical trials for Postoperative Nausea and Vomiting

Intraperitoneal Dexamethasone, Dexmedetomidine, and Dexamethasone-Dexmedetomidine Combination on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

Start date: August 10, 2023
Phase: Phase 3
Study type: Interventional

Nausea and vomiting are some of the most common complaints of patients after any anesthesia, which is often associated with postop-erative pain. The double-blind clinical trial study aimed to compare the prophylactic effect of dexamethasone and dexmedetomidine and their combination in reducing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.

NCT ID: NCT05937282 Recruiting - Dexmedetomidine Clinical Trials

Hemodynamic Responses of Dexmedetomidine, Lidocaine or Propofol Infusions During Laparoscopic Cholecystectomy

Start date: July 1, 2023
Phase: Phase 4
Study type: Interventional

This study will be carried out to compare the efficacy of dexmedetomidine, propofol or lidocaine infusions in attenuation of hemodynamic responses to pneumoperitoneum during adult laparoscopic cholecystectomy using electrical cardiometry.

NCT ID: NCT05794503 Recruiting - Clinical trials for Neuromuscular Blockade

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

Start date: September 11, 2023
Phase: Early Phase 1
Study type: Interventional

This study is intended to be a single-site, prospective, randomized, controlled study that intends to enroll a total of 230 patients undergoing laparoscopic cholecystectomy at Parkland Hospital. Patients will be randomized to receive either neostigmine or sugammadex for reversal of rocuronium-induced neuromuscular blockade. A standardized anesthetic protocol that is usual and customary for the type of operation the patient is having will be provided to the anesthesia teams of enrolled subjects. The remainder of the anesthetic care of the subject will not deviate from the standard of care. To account for protocol deviations and patient dropout, up to 250 randomization envelopes will be made and enrollment will continue until there are 230 completed enrollments.

NCT ID: NCT05533580 Recruiting - General Anesthesia Clinical Trials

Differential Effects of Remimazolam and Propofol on Dynamic Cerebral Autoregulation During General Anesthesia

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Cerebral autoregulation (CA) is the property of the cerebral vascular bed to maintain cerebral perfusion in the presence of changes in blood pressure. In the case of anesthesia, altered cerebral autoregulation, including altered carbon dioxide and hemodilution, can impair physiological changes in the body and lead to poor postoperative prognosis. As a novel ultra-short-acting benzodiazepines drugs, remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. Our study aimed to investigate the different effects of remimazolam and propofol on dynamic cerebral blood flow autoregulation function during general anesthesia.

NCT ID: NCT05533567 Recruiting - General Anesthesia Clinical Trials

Electroencephalographic Profiles During General Anesthesia: a Comparative Study of Remimazolam and Propofol

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

How anesthetic drugs induce and maintain the behavioral state of general anesthesia is an important question in medicine and neuroscience. Different anesthetic drugs act on different molecular targets and neural circuit mechanisms, exhibiting drug-specific EEG features. As a novel ultra-short-acting benzodiazepines drugs, remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aimed to investigate the differences in the characteristics of EEG oscillations during general anesthesia by comparing propofol and remimazolam.

NCT ID: NCT05158270 Recruiting - Clinical trials for Laparoscopic Cholecystectomy

Erector Spinae Plane Block As Alternative Analgesic Modality in Laparoscopic Cholecystectomy

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

Adequate analgesic regimen is one of the most important key elements of Enhanced recovery after surgery (ERAS) protocols. The cornerstone of analgesia is multimodal analgesia combining local anesthetic (LA) techniques and trying to avoid parenteral opioids and their side effects. Anterior quadratus lumborum block (AQLB), compared to other variants of quadratus lumborum blocks (QLBs), was associated with wider and longer sensory blockade, and provided somatic as well as visceral analgesia of the abdomen. The newly emerging, relatively easy erector spinae plane block (ESPB) provided excellent analgesia across a variety of surgical procedures and reduced opioid consumption. This motivated us to do this study to assess and compare the analgesic efficacy of ESPB versus AQLB following laparoscopic cholecystectomy.